Calming

Clomicalm

An aid to the treatment of separation related disorders in dogs

  • Dog

Clomicalm contains Clomipramine hydrochloride, a broad-spectrum tricyclic antidepressant that inhibits the neuronal reuptake of serotonin and norepinephrine. A non-sedative, Clomicalm acts as a useful tool to help combat separation anxiety when used in combination with behavioural modification techniques.

1 in 5 dogs are estimated to be affected by separation anxiety1 and following the growth of dog ownership during lockdown, and the imminent re-opening of workplaces, it is anticipated that veterinary teams will be facing an increase in separation anxiety cases being presented in practice.

Dogs receiving Clomicalm have been shown to have a decreased level of fear and anxiety and an increased receptivity to behavioural modification2. The meat-flavoured tablets are presented in ‘easy to dispense’ 30 tablet packs of 5mg, 20mg & 80mg tablets, and are divisible in two for ease of administration and accurate dosing.

Clomicalm.png

Features & Benefits: 

  • Clomipramine hydrochloride available in three presentations: 5mg, 20mg & 80mg
  • Inhibits the neuronal reuptake of serotonin and norepinephrine
  • Clomipramine is a broad-spectrum tricyclic antidepressant and does not act as a sedative
  • Meat-flavoured tablets to aid acceptance and owner compliance
  • Tablets are divisible in two for ease of administration and accurate dosing
  • Presented in easy to dispense 30 tablet packs

 

309779_Box_CLOMICALM_5MG-x30_GB-IE_right-resize200x200.png309789_Box_CLOMICALM_20MG-x30_GB-IE_right-resize200x200.png309799_Box_CLOMICALM_80MG-x30_GB-IE_right-resize200x200.png

References 1. Salonen, M., Sulkama, S., Mikkola, S., Puurunen, J., Hakanen, E., Tiira, K., Araujo, C. and Lohi, H., 2020. Prevalence, comorbidity, and breed differences in canine anxiety in 13,700 Finnish pet dogs. Scientific Reports, 10(1).
2. US-European Clinical Trial. Internal Data (CLM1998).